ProQR Therapeutics (PRQR) Accounts Payables (2013 - 2025)

ProQR Therapeutics' Accounts Payables history runs 13 years deep, the most recent figure standing at $346885.0 for Q4 2025.

• In Q4 2025, Accounts Payables rose 1928.86% year-over-year to $346885.0; the TTM figure through Dec 2025 stood at $346885.0 (up 1928.86% YoY), while the FY2025 annual figure was $346885.0, up 1928.86% from the prior year.
• Accounts Payables came in at $346885.0 for Q4 2025 at ProQR Therapeutics, up from $17097.5 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.7 million in Q4 2023 to a low of $331.71 in Q1 2021.
• A 5-year average of $482312.8 and a median of $339631.9 in 2021 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables tumbled 99.95% in 2021 and jumped 278695.49% in 2022, its largest moves.
• ProQR Therapeutics' Accounts Payables stood at $218498.5 in 2021, then jumped by 83.04% to $399937.0 in 2022, then soared by 314.57% to $1.7 million in 2023, then sank by 98.97% to $17097.5 in 2024, then soared by 1928.86% to $346885.0 in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $346885.0, $17097.5, and $1.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison